Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 8, 2022

Robust AI Methods for Protein Biotherapeutics: VisualAI™ software for sample-agnostic image analysis with FlowCam

In our new white paper, we present detailed performance results for FlowCam's Artificial Intelligence software, VisualAI, using images of different protein aggregates including monoclonal and polyclonal antibodies and silicone oil that were obtained with multiple FlowCam 8100 instruments. We also demonstrate VisualAI’s effectiveness at measuring protein aggregate content in samples with known ratios of protein aggregates and silicone oil droplets.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.